Home » Policy & Publications » Expert Groups

Expert Groups

FPM has a high level of expertise and knowledge among its membership and we work to make sure that this knowledge is made available to the media, policy makers, and the public, in order to inform and educate in pharmaceutical medicine and raise awareness of the specialty.

The expert groups exist to support and guide FPM in content for external public policy, communications and engagement with FPM members and other relevant stakeholders. They also look internally to ensure that the activities and processes of FPM are adequately representative of their particular area.

If you are interested in joining an Expert Group please email fpm@fpm.org.uk.

Our Expert Groups

  • UK & International Health Policy and Drug Safety
  • Rare Diseases and Advanced Therapies
  • Clinical Trial Science and Regulations
  • Paediatrics and Women’s Health
  • Medical Devices, Diagnostics and Digital Health
  • Oncology Treatments, Access and Screening
  • Anti-infectives and Neurological Treatments

UK & International Health Policy and Drug Safety

Chair: Professor Penny Ward

The ‘UK & International Health Policy and Drug Safety’ group considers government and regulatory consultations, legislation, bills and white papers etc. related to all aspects of healthcare where pharmaceutical R&D, regulatory affairs and medical affairs are impacted. The group’s remit covers all aspects of pharmaceutical medicine – from clinical pharmacology, through phase 1-4 clinical trials, regulatory interactions, to post-licensing monitoring, and drug safety and pharmacovigilance.

The group may also comment on developments in closely related fields, such as the prescribing of medicines, pharmacy, and education and training on the development and use of medicines for all healthcare professionals. The primary focus of the group is on UK legislation, but it also considers global developments and important legislation from key markets around the world.

Rare Diseases and Advanced Therapies

Chair: Dr Zoya Panahloo

The European Union defines a disease or condition as rare if it affects fewer than 1 in 2,000 people within the general population. Currently, there are over 6,000 known rare diseases and new conditions are being described through medical literature on a regular basis. Taken together, the population with a rare disease is significant. Approximately 3.5 million people in the UK will be affected by a rare disease at some point in their lives. Most rare diseases have a genetic cause and 99% of genetic conditions are classed as rare.

A significant proportion of pharmaceutical physicians work in rare diseases. The Rare Diseases and Advanced Therapies Expert Group seeks to support drug discovery across rare diseases, including orphan drugs and advanced therapies and gene therapies. The group also hopes to engage with and educate clinical healthcare professionals and patients, to increase understanding of rare conditions and encourage participation in research.

Clinical Trial Science and Regulations

Chair: TBC

A large number of the FPM members work in clinical research and development, across the phases of drug discovery. The Clinical Trial Science and Regulations Expert Group proactively follows relevant trends in global clinical development matters, including regulatory changes. This includes issues arising from differences in guidance between MHRA, EU/FDA and ICH and other local (UK) and global development ecosystem issues, particularly regarding the Northern Ireland protocol whereby clinical trials are regulated by MHRA and MAAs by EMA. The group considers draft regulatory guidances, policies or other stakeholder materials on clinical development matters.

Paediatrics and Women’s Health

Chair: Dr Raja Rajaram

For many reasons, children and women are groups that are often overlooked in the development of novel medicines. The Paediatrics and Women’s Health expert group considers the scientific, ethical and regulatory challenges across pharmaceutical medicine in children and women at all stages of life course. Children are not just small adults – the . Women too, have many distinct biological differences

The group also considers the patient issues relevant to these groups – how to support children to make choices in their healthcare, working with parents and carers and others.

Medical Devices, Diagnostics and Digital Health

Chair: Dr Bob Holland

The Medical Devices, Diagnostics and Digital health Expert Group consider discovery, development, regulatory processes and vigilance processes across these areas.
External therapeutic devices (eg mechanical ventilators), implantable devices, in vitro diagnostics (in particular we are interested in novel molecular diagnostics and companion diagnostics), wearable technologies and digital therapeutics (eg Apps to support behavioural interventions).
There is some overlap with eHealth but we do not regard this as within our remit per se.

The group also consider the impact that innovation in these areas has on ‘traditional medicines’.

Oncology Treatments, Access and Screening

Chair: Dr Claire Barton

The Oncology Treatments, Access and Screening Expert Group covers the development of treatments for all types of cancers, including systemic anti-cancer agents, radiotherapy, oncology-related devices and diagnostics, and drug-device combinations. This includes exploratory and translational research. The group also considers associated public and clinical issues around cancer, for instance prevention (for example in individuals with rare inherited cancer-predisposition syndromes) and screening.

The group also considers patient issues, such as participation in clinical trials, and issues around informed consent of particular relevance to cancer patients e.g. need for/legitimacy of mandatory biopsies, risk-benefit in subjects with very short life-expectancy, availability of standard/approved therapies in different geographic regions, and patient support and guidance, including palliative care. Marketing and access to treatments for cancer and the development of regulatory guidelines in oncology also fall under the group’s remit.

Anti-infectives and Neurological Treatments

Chair: Dr Carlo Berti

Join an expert group or share ideas for new expert groups

Get Involved

Email Ben Cottam, Head of Policy and Communication

Membership of the Expert Groups is open to all suitably qualified and experienced FPM members (all grades).

Members of the groups must be confident that their level of expert knowledge is such that their input could be considered the official FPM position.

Example outputs from some of our Expert Groups